Zenas BioPharma Inc. (ZBIO)
7.83
-0.60 (-7.12%)
At close: Apr 03, 2025, 3:59 PM
7.84
0.08%
Pre-market: Apr 04, 2025, 04:07 AM EDT
-7.12% (1D)
| Bid | 6.5 |
| Market Cap | 327.22M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -11.89 |
| PE Ratio (ttm) | -0.66 |
| Forward PE | -1.76 |
| Analyst | Buy |
| Ask | 7.97 |
| Volume | 176,335 |
| Avg. Volume (20D) | 185,960 |
| Open | 7.80 |
| Previous Close | 8.43 |
| Day's Range | 7.62 - 8.09 |
| 52-Week Range | 5.83 - 26.25 |
| Beta | -3.62 |
About ZBIO
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclo...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 13, 2024
Employees 130
Stock Exchange NASDAQ
Ticker Symbol ZBIO
Website https://zenasbio.com
Analyst Forecast
According to 7 analyst ratings, the average rating for ZBIO stock is "Buy." The 12-month stock price forecast is $32.5, which is an increase of 315.07% from the latest price.
Stock Forecasts
